Atossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $0.72 on Wednesday. Atossa Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.31. The company has a market cap of $91.05 million, a PE ratio of -3.29 and a beta of 1.20. The stock’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.11.

Atossa Therapeutics (NASDAQ:ATOS) last posted its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, equities analysts predict that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Intech Investment Management LLC acquired a new position in shares of Atossa Therapeutics during the third quarter valued at about $29,000. The Manufacturers Life Insurance Company bought a new stake in Atossa Therapeutics during the 3rd quarter worth approximately $75,000. State Street Corp raised its stake in shares of Atossa Therapeutics by 4.2% in the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after purchasing an additional 69,180 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after purchasing an additional 24,951 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Atossa Therapeutics by 280.9% during the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after buying an additional 123,683 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.